ESPL1 Polyclonal antibody

ESPL1 Polyclonal Antibody for WB, ELISA
Cat No. 22261-1-AP

产品说明书

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

WB, ELISA

Caspase like protein ESPL1, ESP1, KIAA0165, SEPARASE, SEPARIN

缓冲液配方:  PBS and Azide
PBS and Azide
偶联物:  Unconjugated
Unconjugated
规格价格库存


经过测试的应用

Positive WB detected inA431 cells, Jurkat cells, Raji cells

推荐稀释比

应用推荐稀释比
Western Blot (WB)WB : 1:500-1:1000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

22261-1-AP targets ESPL1 in WB, ELISA applications and shows reactivity with human samples.

经测试应用 WB, ELISA Application Description
经测试反应性 human
免疫原 Peptide 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Polyclonal
产品类型 Antibody
全称 extra spindle pole bodies homolog 1 (S. cerevisiae)
别名 Caspase like protein ESPL1, ESP1, KIAA0165, SEPARASE, SEPARIN
计算分子量 233 kDa
观测分子量170 kDa
GenBank蛋白编号NM_012291
基因名称 ESPL1
Gene ID (NCBI) 9700
偶联类型 Unconjugated
形式Liquid
纯化方式Antigen affinity purification
UNIPROT IDQ14674
储存缓冲液 PBS with 0.02% sodium azide and 50% glycerol, pH 7.3.
储存条件Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

ESPL1 (Extra spindle poles-like 1 protein), also known as Separin, Separase, a cysteine endopeptidase, plays a vital role in the stable binding between sister chromatids before anaphase and their timely separation during anaphase, which is the key to chromosome inheritance (PMID: 34512713). ESPL1 expression is elevated and predicts poor outcomes in patients with various types of cancer, including breast cancer, glioma and endometrial cancer (PMID: 36465268). Full-length ESPL1 decreased after 30 min resulting in a ~ 170 kDa N-terminal (ESPL1N−term) and a ~ 60 kDa C-terminal polypeptide (ESPL1CC−term), reflecting ESPL1 activation and auto-cleavage (PMID: 30429481)

实验方案

Product Specific Protocols
WB protocol for ESPL1 antibody 22261-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...